Like tech stocks in general, artificial intelligence exchange traded funds are on a tear in 2023 as investors look to play the burgeoning trend.
10 stocks that fit Warren Buffett’s takeover criteria
Warren Buffett watchers are speculating which companies he’s eyeing to deploy his $100-billion-plus war chest.
Electric Ram pickup debuts in Super Bowl ad that pokes fun at rivals, sex-drug commercials
The Ram Super Bowl spot spoofs ads for male sex-enhancement drugs using electric truck owners discussing problems they’ve had with their pickups.
Ukraine holds defense as battles rage in Donetsk region, top commander says
The commander-in-chief of Ukraine’s Armed Forces said Russia carries out some 50 attacks daily in Donetsk.
A new high-altitude flying object shot down over Northern Canada, Prime Minister Justin Trudeau says
Canadian Prime Minister Justin Trudeau on Saturday said he had ordered the takedown of an object that was flying at a high altitude over Canada.
Elon Musk’s Neuralink is under investigation for possible unsafe transport of contaminated hardware
Elon Musk’s Neuralink under investigation by the U.S. Department of Transportation for allegedly handling contaminated hardware in an unsafe manner.
The ChatGPT AI hype cycle is peaking, but even tech skeptics don’t expect a bust
The metaverse was the next big thing and now it’s generative AI. We asked top tech executives to cut through the hype. They say this one’s for real.
Why passkeys from Apple, Google, Microsoft may soon replace your passwords
Passkeys, which require you to accept a prompt on a secondary device when you log into an account, are on the path to replace password logins.
Virtual assisting is a side hustle that can pay as much as $100 an hour—here’s how to get started
There are many side hustles suited for Gen Z, like affiliate marketing and secret shopping. Virtual assisting can lean into your skills and offers flexibility.
Radioligand therapy, a ‘game-changer’ for cancer treatment, forces manufacturers to race against a ticking clock
Radioligand therapy is a ‘game -hanger’ for cancer treatment, but it forces manufacturers to race against a ticking clock.